Literature DB >> 18159036

Recent developments in the management of acute respiratory distress syndrome in adults.

Heather R Bream-Rouwenhorst1, Elizabeth A Beltz, Mary B Ross, Kevin G Moores.   

Abstract

PURPOSE: Recent developments in the management of acute respiratory distress syndrome (ARDS) in adults are reviewed.
SUMMARY: Corticosteroids have been extensively studied in ARDS; however, they have not demonstrated clear benefit in patients with ARDS. Some trials have found increased complications and mortality related to corticosteroid use. The use of conservative fluid management has been associated with significant reductions in morbidity, highlighting the need to avoid fluid over-administration in patients with ARDS. A number of ventilatory strategies have also been studied. Studies have found that higher positive end-expiratory pressure settings do not appear to be harmful in patients with ARDS. In an effort to prevent alveolar overdistention, low tidal volume and plateau pressure ventilation is increasingly being used in patients with acute lung injury (ALI). Given the increasing evidence supporting the use of lower tidal volume ventilation, this strategy has become the new standard of care in patients with suspected ALI and ARDS. No clear benefit has been shown in the treatment of ARDS with nitric oxide and surfactant. Prostaglandins and acetylcysteine are not considered useful in the treatment of ARDS, while no conclusions can be drawn regarding the benefits of albuterol on mortality in patients with ARDS. The use of prone positioning should be discouraged in the treatment of ARDS based on its associated risks.
CONCLUSION: Early administration of moderate-dosage corticosteroids likely helps decrease the time of ventilator dependence and duration of intensive care unit stay. Conservative fluid management and low tidal volume ventilation are becoming increasingly widespread in the management of patients with ARDS. Nitric oxide, surfactant, prostaglandins, albuterol, acetylcysteine, and prone positioning have not been shown to be beneficial in the treatment of ARDS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18159036     DOI: 10.2146/ajhp060530

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

Review 1.  Integrating microRNAs into a system biology approach to acute lung injury.

Authors:  Tong Zhou; Joe G N Garcia; Wei Zhang
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

2.  A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles.

Authors:  Sok Bee Lim; Israel Rubinstein; Ruxana T Sadikot; James E Artwohl; Hayat Önyüksel
Journal:  Pharm Res       Date:  2010-11-25       Impact factor: 4.200

Review 3.  Epithelial Dysfunction in Lung Diseases: Effects of Amino Acids and Potential Mechanisms.

Authors:  Jingqing Chen; Yuhang Jin; Ying Yang; Zhenlong Wu; Guoyao Wu
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  H1N1-associated acute respiratory distress syndrome.

Authors:  Tathagat Narula; Mathew Safley; Bennett P deBoisblanc
Journal:  Am J Med Sci       Date:  2010-12       Impact factor: 2.378

5.  Advocating "spine damage control" as a safe and effective treatment modality for unstable thoracolumbar fractures in polytrauma patients: a hypothesis.

Authors:  Philip F Stahel; Michael A Flierl; Ernest E Moore; Wade R Smith; Kathryn M Beauchamp; Anthony Dwyer
Journal:  J Trauma Manag Outcomes       Date:  2009-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.